• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals Inc (NQ: ABOS )

    2.845 -0.035 (-1.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Acumen Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 Next >
    Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024
    ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Trading SMID Biotech Stocks In A Volatile Market
    Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
    Via Talk Markets
    ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
    ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
    ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 26, 2024
    Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
    Via Benzinga
    Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.